Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should benefit from the addition of products acquired from Abbott Laboratories (Feb 2015), Pharma (Nov 2015) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 9.82%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings In-line: Zoetis reported an in-line earnings per share with estimates in second-quarter 2017. The company reported an EPS of 53 cents.
Revenues Beat: Zoetis posted revenues of $1.27 billion surpassing the Zacks consensus estimate of $1.25 billion.
Key Stats: The company strengthened its canine dermatology portfolio with the approval of Clavamox Chewable in the U.S. in May 2017 for use in dogs. The company completed the acquisition of Nexvet Biopharma plc in Jul 2017, which develops monoclonal antibody therapies for management of chronic pain and other therapeutic areas in companion animals. With this acquisition, Zoetis strengthens its monoclonal antibodies pipeline.
2017 Outlook Upgraded: Zoetis increased its outlook for 2017. In 2017, the company expects earnings in the range of $2.30 to $2.37 per share on revenues of $5.15 billion and $5.25 billion. The Zacks Consensus Estimate for earnings is $2.33 per share on revenues of $5.2 billion.
Share Price Impact: Shares of the company were up 0.26% in-pre-market trading.
Check back later for our full write up on this ZTS earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should benefit from the addition of products acquired from Abbott Laboratories (Feb 2015), Pharma (Nov 2015) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 9.82%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings In-line: Zoetis reported an in-line earnings per share with estimates in second-quarter 2017. The company reported an EPS of 53 cents.
Revenues Beat: Zoetis posted revenues of $1.27 billion surpassing the Zacks consensus estimate of $1.25 billion.
Key Stats: The company strengthened its canine dermatology portfolio with the approval of Clavamox Chewable in the U.S. in May 2017 for use in dogs. The company completed the acquisition of Nexvet Biopharma plc in Jul 2017, which develops monoclonal antibody therapies for management of chronic pain and other therapeutic areas in companion animals. With this acquisition, Zoetis strengthens its monoclonal antibodies pipeline.
2017 Outlook Upgraded: Zoetis increased its outlook for 2017. In 2017, the company expects earnings in the range of $2.30 to $2.37 per share on revenues of $5.15 billion and $5.25 billion. The Zacks Consensus Estimate for earnings is $2.33 per share on revenues of $5.2 billion.
Share Price Impact: Shares of the company were up 0.26% in-pre-market trading.
Check back later for our full write up on this ZTS earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ZTS - FREE